4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors

4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors

Local anesthetics (LAs) reversibly prevent the generation and conduction of electrical impulses in excitable membranes (nerves, cardiac myocytes, skeletal muscle). They are fundamental to regional anesthesia, peripheral nerve blocks, neuraxial anesthesia, and multimodal pain pathways.

---

1. Molecular Mechanism of Action & State-Dependent Blockade

Local anesthetics inhibit nerve conduction by binding to a specific receptor site on the $\alpha$-subunit of voltage-gated sodium ($Na_v$) channels, physically occluding the channel pore from the inside and halting inward $Na^+$ current.

Extracellular Fluid (pH 7.4)          Lipid Bilayer (Axolemma)          Intracellular Cytosol (pH 7.1)
───────────────────────────────────────────────────────────────────────────────────────────────────
[BH+]  ◄════►  [B] + [H+]  ───►  [B] (Un-ionized Base)  ───►  [B] + [H+]  ◄════►  [BH+] (Cation)
(Cannot Cross                  (Crosses Axolemma)                                     │
 Membrane)                                                                           ▼
                                                                           Binds Inner Na+ Pore
                                                                           (Blocks Na+ Influx)

The Dual-Form Penetration and Binding Paradigm

Local anesthetics are weak bases with a tertiary amine group. In aqueous solution, they exist in equilibrium between an un-ionized, lipophilic free base form ($B$) and an ionized, hydrophilic conjugate acid cation ($BH^+$):

$BH^+ \rightleftharpoons B + H^+ \quad \text{where} \quad pH = pKa + \log\left(\frac{[B]}{[BH^+]}\right)$

1. Membrane Penetration: The un-ionized lipophilic base ($B$) readily diffuses across the hydrophobic phospholipid axolemma into the neuronal cytoplasm.
2. Channel Receptor Binding: Once intracellular, the base re-equilibrates into the ionized protonated cation ($BH^+$). The charged $BH^+$ molecule enters the open channel pore and binds with high affinity to the receptor site on the inner vestibule of the $Na_v$ $\alpha$-subunit.

Use-Dependent (Phasic) vs. Tonic Blockade

Voltage-gated sodium channels cycle through three distinct conformational states: Resting (Closed) $\rightarrow$ Active (Open) $\rightarrow$ Inactive (Refractory).

• Local anesthetics exhibit use-dependent (phasic) block: they bind with significantly greater affinity to channels in the open (active) and inactivated (refractory) states than in the closed (resting) state.
• Consequently, rapidly firing neurons (such as nociceptive pain fibers during surgical trauma, or rapid cardiac tachyarrhythmias) spend more time in open and inactivated states, accumulating local anesthetic molecules faster and exhibiting a deeper block than quiescent fibers.

Differential Nerve Fiber Sensitivity

Nerve fibers are classified based on diameter, myelination, and conduction velocity. Sensitivity to local anesthetic blockade follows a distinct hierarchy:

Clinical Sequence of Differential Blockade: $\text{Autonomic (B fibers)} \rightarrow \text{Temperature/Pain (A}\delta\text{, C)} \rightarrow \text{Touch/Pressure (A}\beta\text{)} \rightarrow \text{Motor (A}\alpha\text{)}$

2. Chemical Structure & Classification: Amino Esters vs. Amino Amides

All local anesthetic molecules share a fundamental three-part chemical architecture:

1. Lipophilic Aromatic Ring: Benzene derivative that determines lipid solubility, membrane penetration, and intrinsic anesthetic potency.
2. Intermediate Hydrocarbon Chain: Connects the aromatic ring to the amine group via either an Ester ($-COO-$) or an Amide ($-NH-CO-$) bond. Dictates the metabolic pathway, duration, and allergic potential.
3. Hydrophilic Tertiary Amine: Weak base containing nitrogen that accepts hydrogen ions, dictating the $pKa$ and degree of ionization at physiologic pH.

[Lipophilic Aromatic Ring] ─────── [Intermediate Linkage: Ester or Amide] ─────── [Hydrophilic Tertiary Amine]
 (Potency & Lipid Partition)                 (Metabolic Fate & Allergy)                 (pKa & Ionization)

The Spelling Rule for Identification

• Amino Amides contain an "i" in the drug name prefix before the suffix "-caine":
  • Lidocaine, Bupivacaine, Ropivacaine, Mepivacaine, Prilocaine, Levobupivacaine, Articaine (contains both an amide and a thiophene ester ring).
• Amino Esters do NOT contain an "i" in the drug name prefix before the suffix "-caine":
  • Cocaine, Procaine, Tetracaine, Chloroprocaine, Benzocaine.

Pharmacologic Comparison: Esters vs. Amides

3. Physicochemical Determinants of Clinical Performance

Three physicochemical properties govern the clinical onset, potency, and duration of all local anesthetics:

1. $pKa$ $\rightarrow$ Speed of Onset

• Definition: The $pKa$ is the pH at which the drug is 50% un-ionized base ($B$) and 50% ionized cation ($BH^+$).
• Mechanism: Because all local anesthetics have $pKa$ values above 7.4 (ranging from 7.6 to 9.1), they exist predominantly as ionized cations ($BH^+$) at physiologic pH. The closer the $pKa$ is to physiologic pH (7.4), the higher the percentage of un-ionized lipophilic base ($B$), allowing faster diffusion across the nerve sheath and resulting in a faster speed of onset.
• The Acidosis/Infection Trap: In infected or inflamed tissue, local pH drops to 5.5–6.0. According to the Henderson-Hasselbalch equation, severe acidosis shifts the equilibrium overwhelmingly toward the charged $BH^+$ form ($>99%$ ionized), preventing the uncharged base from penetrating the axolemma and causing local anesthetic failure.
• Sodium Bicarbonate Alkalinization: Adding $1\text{ mL}$ of $8.4%\ NaHCO_3$ to $10\text{ mL}$ of $1%\text{ or } 2%$ lidocaine increases the solution pH, elevating the un-ionized base fraction ($B$). This accelerates onset of sensory block, deepens the block quality, and significantly reduces the stinging pain of injection.

2. Lipid Solubility $\rightarrow$ Anesthetic Potency

• Definition: Measured by the octanol:water partition coefficient.
• Mechanism: Axolemmal membranes and myelin sheaths are 90% lipid. Highly lipid-soluble agents (Bupivacaine, Tetracaine, Ropivacaine) penetrate hydrophobic membranes with extreme ease, requiring a much smaller molar dose to achieve conduction block $\rightarrow$ High Potency (formulated as 0.25% to 0.5% solutions). Low lipid-soluble agents (Procaine, Chloroprocaine, Mepivacaine, Lidocaine) require higher concentrations (1.0% to 3.0%).

3. Protein Binding $\rightarrow$ Duration of Action

• Definition: Percentage of drug bound to plasma and tissue proteins, primarily $\alpha_1$-acid glycoprotein (AAG) (high affinity, low capacity) and albumin (low affinity, high capacity).
• Mechanism: The degree of plasma protein binding directly mirrors the drug's binding affinity for protein receptor sites on the sodium channel. High protein binding creates a tissue depot at the receptor site, yielding a prolonged duration of action.

Summary Table of Physicochemical Constants & Dosing Limits

4. Vasoconstrictor Additives & Tissue Absorption Kinetics

Epinephrine Additive Dynamics (1:200,000 = 5 mcg/mL)

Co-administering epinephrine (1:200,000 or $5\ \mu\text{g/mL}$) with local anesthetics produces four major clinical effects:

1. Decreases Systemic Absorption: Stimulates local vascular $\alpha_1$-adrenergic receptors, causing vasoconstriction that slows the rate of vascular uptake by 20% to 50%.
2. Reduces Peak Blood Levels ($C_{max}$): Flattens the plasma concentration curve, significantly diminishing the risk of Local Anesthetic Systemic Toxicity (LAST).
3. Prolongs Duration of Action: Keeps local anesthetic molecules localized around the nerve bundle for a longer duration (most pronounced for short- and intermediate-acting agents like lidocaine and mepivacaine; less pronounced for highly lipophilic agents like bupivacaine, which are already tightly bound to tissues).
4. Intravascular Injection Marker: Serves as a vital test dose marker ($15\ \mu\text{g}$ epinephrine in 3 mL). Inadvertent intravascular injection triggers an acute heart rate increase $\ge 10\text{ to } 20\text{ bpm}$ or systolic blood pressure rise $\ge 15\text{ mmHg}$ within 30 to 60 seconds in non-beta-blocked patients.

Vascular Absorption Rates by Anatomical Block Site (ICEBS Mnemonic)

The peak systemic absorption rate and potential for toxicity depend directly on the vascularity of the injection site:

$\mathbf{I} \text{ (Intravascular)} > \mathbf{I} \text{ (Intercostal)} > \mathbf{C} \text{ (Caudal)} > \mathbf{E} \text{ (Epidural)} > \mathbf{B} \text{ (Brachial Plexus)} > \mathbf{S} \text{ (Sciatic / Femoral)} > \mathbf{S} \text{ (Subcutaneous)}$

$\mathbf{I}\text{-}\mathbf{BICEPS:}\ \text{Intravenous } > \text{ Intercostal } > \text{ Caudal } > \text{ Epidural } > \text{ Brachial Plexus } > \text{ Sciatic/Femoral } > \text{ Subcutaneous}$

• Intercostal nerve blocks yield the highest peak plasma drug concentrations ($C_{max}$) among all regional techniques due to the immense vascularity of the intercostal neurovascular bundle.
• Subcutaneous infiltration exhibits the lowest vascular uptake and slowest absorption.

---

5. Drug-Induced Methemoglobinemia

Methemoglobinemia occurs when the normal ferrous iron ($Fe^{2+}$) within the heme moiety of hemoglobin is oxidized to the ferric state ($Fe^{3+}$). Ferric heme cannot bind oxygen and causes an allosteric leftward shift of the oxyhemoglobin dissociation curve in remaining normal heme groups, severely impairing oxygen offloading to peripheral tissues.

Normal Hemoglobin (Fe2+ Ferrous) ───[Oxidation by o-Toluidine / Benzocaine]───► Methemoglobin (Fe3+ Ferric)
                                                                                        │
                                                                                        ▼
Pulse Oximeter Fixed at ~85% ◄─── Left Shift of Oxy-Hgb Curve ◄─── Incapable of Binding Oxygen

Causative Anesthetic Agents

1. Prilocaine: Metabolized in the liver and lungs to ortho-toluidine, a potent oxidizing agent. Toxicity typically occurs at doses $>600\text{ mg}$ ($>8\text{ mg/kg}$).
2. Benzocaine: High-concentration topical sprays (e.g., Hurricaine spray 20%, Cetacaine) used for awake fiberoptic intubation, endoscopy, or TEE probe placement. Even short 1- to 2-second sprays can precipitate fulminant methemoglobinemia.
3. EMLA Cream: Eutectic Mixture of Local Anesthetics (2.5% Lidocaine + 2.5% Prilocaine); excessive topical application in neonates and infants with immature methemoglobin reductase pathways.

Clinical Presentation & Diagnostics

• Symptoms: Grayish-blue cyanosis refractory to 100% inspired oxygen, fatigue, headache, tachypnea, metabolic lactic acidosis, altered mental status, and syncope.
• Physical Exam: Arterial blood drawn displays a distinct, non-clotting dark chocolate-brown color that does not turn bright red when exposed to atmospheric air.
• Pulse Oximetry Artefact: The standard pulse oximeter ($SpO_2$) reads falsely fixed at approximately 85%, regardless of the true arterial oxygenation. This occurs because methemoglobin absorbs both 660 nm (red) and 940 nm (infrared) wavelengths equally (1:1 absorbance ratio), which the oximeter microprocessor interprets as an $SpO_2$ of 85%.
• Gold Standard Diagnosis: Co-oximetry blood gas analysis, which measures the exact percentage of methemoglobin (MetHb > 15–20% causes symptomatic cyanosis; MetHb > 50–70% is lethal).

Definitive Management: Methylene Blue Protocol

$\text{Methylene Blue Dose: } \mathbf{1.0\text{ to } 2.0\text{ mg/kg IV}} \text{ over 5 minutes}$

• Mechanism: Methylene blue acts as an exogenous electron acceptor cofactor for NADPH-methemoglobin reductase, accelerating the enzymatic reduction of ferric iron ($Fe^{3+}$) back to ferrous iron ($Fe^{2+}$).
• Contraindications & Warnings:
  • Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: Patients lack NADPH generated by the hexose monophosphate shunt. Administering methylene blue is ineffective and triggers severe acute hemolytic anemia. Treatment in G6PD: Ascorbic acid (Vitamin C 300–500 mg/day) and hyperbaric oxygen.
  • Serotonergic Antidepressants (SSRIs / SNRIs / MAOIs): Methylene blue is a potent monoamine oxidase-A (MAO-A) inhibitor; co-administration can precipitate life-threatening Serotonin Syndrome.

6. Local Anesthetic Systemic Toxicity (LAST) & 20% Lipid Emulsion Rescue

Local Anesthetic Systemic Toxicity (LAST) is a life-threatening complication resulting from accidental intravascular injection or massive systemic absorption of local anesthetics.

Clinical Progression of LAST

Because the central nervous system is more sensitive to local anesthetic toxicity than the cardiovascular system, CNS signs classically precede cardiovascular collapse:

1. Early CNS Excitation (Subjective / Cortical): Circumoral paresthesias, tongue numbness, metallic taste, tinnitus, lightheadedness, visual disturbances, and slurred speech.
2. Advanced CNS Excitation (Motor / Subcortical): Shivering, involuntary muscle twitching, facial tremors, and generalized tonic-clonic grand mal seizures (caused by selective blockade of inhibitory cortical interneurons, leaving unopposed excitatory NMDA pathways).
3. CNS Depression: Global CNS depression, loss of consciousness, coma, and central apnea.
4. Cardiovascular Toxicity: Biphasic response. Initial transient sympathetic surge (hypertension, tachycardia), followed rapidly by profound myocardial depression, peripheral vasodilation, conduction delays (prolonged PR, widened QRS), sinus bradycardia, ventricular dysrhythmias (Torsades de pointes, ventricular fibrillation), and asystole.

Bupivacaine Cardiotoxicity vs. Lidocaine ($CC/CNS$ Ratio)

• The CC/CNS Ratio: The ratio of the drug dose required to produce Cardiovascular Collapse compared to the dose required to produce CNS seizures ($CC/CNS$ ratio).
  • Lidocaine: $CC/CNS\text{ ratio} = \mathbf{7.1}$. Lidocaine provides a broad safety margin; severe CNS toxicity and seizures appear well before cardiovascular toxicity manifests.
  • Bupivacaine: $CC/CNS\text{ ratio} = \mathbf{3.7}$. Bupivacaine has a very narrow margin of safety; fatal cardiac arrhythmias can occur almost simultaneously with seizures.
• The "Fast In, Slow Out" Kinetic Trap: Bupivacaine binds rapidly to open and inactivated cardiac $Na_v1.5$ sodium channels during ventricular systole ("fast in"), but dissociates from resting channels during diastole extremely slowly ("slow out", $t_{1/2} > 150\text{ s}$ compared to $<0.2\text{ s}$ for lidocaine). Bupivacaine accumulates on cardiac channels at normal heart rates, generating profound conduction blocks, re-entrant ventricular fibrillation, and electromechanical dissociation.
• $S-(-)$ Enantiomers (Ropivacaine & Levobupivacaine): Formulated as pure single enantiomers. The $S$-isomer has significantly lower affinity for cardiac sodium channels than the $R-(+)$ isomer of racemic bupivacaine, providing a wider safety margin and higher $CC/CNS$ ratio.

ASRA LAST Treatment Protocol & 20% Lipid Emulsion Guidelines

Immediate Actions & Supportive Care

1. Stop Injection Immediately: Discontinue local anesthetic administration at the first sign of toxicity.
2. Call for Help & Retrieve LAST Rescue Kit: Request the local anesthetic rescue cart and 20% Lipid Emulsion (Intralipid) immediately. Alert the nearest cardiopulmonary bypass / ECMO team.
3. Airway & Ventilation: Ventilate with 100% $O_2$. Hyperventilate mildly to prevent hypoxia, hypercapnia ($PaCO_2 \uparrow$), and acidosis ($pH \downarrow$), all of which exacerbate LAST by increasing cerebral blood flow (delivering more local anesthetic to the brain), displacing local anesthetic from plasma proteins, and reducing the seizure threshold.
4. Seizure Control: Administer Midazolam (1 to 2 mg IV) or other benzodiazepines. Avoid large doses of propofol, which further depress myocardial contractility.

Critical ACLS Resuscitation Modifications

• Reduce Epinephrine Doses: Use small initial doses of Epinephrine $<1\ \mu\text{g/kg}$ (e.g., 10 to 100 mcg boluses in adults). Standard large ACLS doses (1 mg) worsen lipid resuscitation, impair myocardial microvascular perfusion, and trigger severe ventricular arrhythmias.
• AVOID Vasopressin: Strictly contraindicated; vasopressin worsens pulmonary edema, increases afterload, and impairs resuscitation outcomes.
• AVOID Calcium Channel Blockers and $\beta$-Blockers: Exacerbate myocardial depression and heart block.
• AVOID Local Anesthetic Antiarrhythmics (Lidocaine, Procainamide): Lidocaine adds to the systemic local anesthetic burden.
• Amiodarone is the antiarrhythmic of choice for ventricular dysrhythmias.

20% Lipid Emulsion Dosing Protocol (Actual Body Weight)

\mathbf{Initial\ Bolus:} & \quad \mathbf{1.5\text{ mL/kg IV}} \text{ over 2 to 3 minutes } (\approx 100\text{ mL for a } 70\text{ kg adult}) \\[4pt] \mathbf{Continuous\ Infusion:} & \quad \mathbf{0.25\text{ mL/kg/min IV}} (\approx 18\text{ mL/min or } 1000\text{ mL/hr for } 70\text{ kg}) \\[4pt] \mathbf{Re-bolus\ Criteria:} & \quad \text{If cardiovascular instability persists, repeat } 1.5\text{ mL/kg bolus once or twice} \\[2pt] & \quad \text{every 3–5 minutes and double infusion rate to } \mathbf{0.5\text{ mL/kg/min}} \\[4pt] \mathbf{Maximum\ Total\ Dose:} & \quad \mathbf{12\text{ mL/kg IV}} \text{ over the first 30 minutes} \end{aligned}$$ - **Mechanisms of Lipid Emulsion Therapy:** - **Lipid Sink Theory:** Acts as an intravascular lipid compartment that extracts lipophilic local anesthetic molecules from highly perfused target tissues (heart and brain). - **Metabolic Activation:** Overcomes local anesthetic-induced inhibition of mitochondrial carnitine acyltransferase, providing fatty acid substrates for myocardial ATP production. - **Direct Positive Inotropic & Membrane Effects:** Restores intracellular calcium handling and reverses cardiac sodium channel blockade.